The FDA has granted a priority review designation to a new drug application (NDA) for quizartinib for the treatment of adult patients with relapsed/refractory FLT3
-ITD–positive acute myeloid leukemia (AML), according to Daiichi Sankyo, the manufacturer of the FLT3 inhibitor.
The priority designation, which follows a breakthrough therapy designation, is based on findings from the phase III QuANTUM-R study. Results from the trial presented at the 2018 EHA Congress showed that quizartinib reduced the risk of death by 24% compared with salvage chemotherapy in patients with FLT3
-ITD–positive relapsed/refractory AML after first-line treatment with or without hematopoietic stem cell transplantation (HSCT).
At a median follow-up of 23.5 months, the median overall survival (OS) was 6.2 months (95% CI, 5.2-7.2) with quizartinib compared with 4.7 months (95% CI, 4.0-5.5) with salvage chemotherapy (HR, 0.76; 95% CI, 0.58-0.98; stratified log-rank test, 1-sided P
... to read the full story